drugset / Trial / NCT06094790

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

NCT06094790

Phase 1 Completed 32 enrolled Corcept Therapeutics
RandomizedParallel-groupOpen-labelOther

Summary

A study designed to characterize the plasma pharmacokinetic (PK) profile of CORT125134 in healthy subjects receiving once-daily oral administration of the current capsule formulation of CORT125134 for 14 days.

Timeline

Start
2017-05-18
Primary completion
2017-11-15
Completion
2017-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Relacorilant Small molecule 150 mg Oral
Subject Relacorilant Small molecule 250 mg Oral

Indications

No indication recorded.